Gary Ulaner, MD, PhD, FSNMMI, FACNM, of Hoag Family Cancer Institute, highlight’s 2 new clinical trials for prostate cancer staging and treatment: MIRROR and 177Lu-PNT2002. Hoag is the first site in the world to enroll patients in these trials.
MIRROR will investigate Piflufolastat F 18 with a whole-body PET/CT scan in patients with favorable intermediate-risk prostate cancer to determine its utility in identifying cancer confined to the prostate gland or spread to other areas.
The 177Lu-PNT2002 Expanded Access Protocol will look at PSMA-targeted therapy prior to chemotherapy in patients with metastatic prostate cancer.
![Black women are more likely to die from cancer when diagnosed, study shows [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_352681_0_6061cc016fa845ecb7ab6ab2055fe9e21140x641jpg.jpg)
![Street Outlaws star Lizzy Musi shared gut-wrenching message about Nascar driver boyfriend Jeffrey Earnhardt before death [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/06/mp_348837_0_pdUNCONDITIONALLOVEOPjpg.jpg)
